Anbc, Inc. (SYUP)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Anbc, Inc. (SYUP) trades at $0.00 with AI Score 51/100 (Grade B). Anbc, Inc. , operating as Shanghai Yutong Pharma, develops, manufactures, and commercializes traditional Chinese medicines and biological pharmaceuticals. Market cap: $15,921, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for SYUP: SYUP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SYUP against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SYUP: 4/6 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Anbc, Inc. (SYUP) Healthcare & Pipeline Overview
Shanghai Yutong Pharma (SYUP) focuses on traditional Chinese herbal medicines and biological pharmaceuticals, offering products like Qilisheng and Qi-ju-di-huang. Operating in the People's Republic of China, the company distributes through wholesale channels, emphasizing immune support, organ protection, and symptom relief in the specialty and generic drug market.
What Is the Investment Thesis for SYUP?
Anbc, Inc. (SYUP) operates within the traditional Chinese medicine market, demonstrating a high profit margin of 41.1% and a gross margin of 49.1%. The company's focus on traditional herbal medicines and biological pharmaceuticals caters to a specific segment within the Chinese healthcare market. Growth catalysts include expanding distribution networks and introducing new products within its existing therapeutic areas. However, the company faces risks associated with operating on the OTC market, including potential liquidity constraints and disclosure requirements. The company's beta of -6.47 suggests a low correlation with the overall market, potentially offering diversification benefits. The company's P/E ratio is 0.02.
Based on FMP financials and quantitative analysis
SYUP Key Highlights
- Profit Margin of 41.1% indicates strong profitability in the traditional Chinese medicine market.
- Gross Margin of 49.1% reflects efficient cost management in the production of herbal medicines and biological pharmaceuticals.
- Beta of -6.47 suggests a low correlation with the overall market, potentially offering diversification benefits.
- The company operates in the growing Chinese pharmaceutical market, which is driven by increasing healthcare spending and an aging population.
- P/E ratio of 0.02 indicates a potentially undervalued stock.
Who Are SYUP's Competitors?
SYUP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SYUP's Key Strengths?
- Established presence in the Chinese pharmaceutical market.
- Proprietary formulations of traditional Chinese medicines.
- High profit margin of 41.1%.
- Gross margin of 49.1%.
What Are SYUP's Weaknesses?
- Reliance on the Chinese market.
- Limited product diversification.
- OTC listing may limit access to capital.
- Unknown disclosure status.
What Could Drive SYUP Stock Higher?
- Potential new product launches in the traditional Chinese medicine market.
- Expansion of distribution network within China.
- Strategic partnerships with other pharmaceutical companies.
- E-commerce and online sales initiatives.
- Potential international expansion into new markets.
What Are the Key Risks for SYUP?
- Competition from other pharmaceutical companies in China.
- Regulatory changes in the Chinese pharmaceutical market.
- Fluctuations in the Chinese economy.
- Product liability claims.
- Limited liquidity due to OTC listing.
What Are the Growth Opportunities for SYUP?
- Expanding Distribution Network: Anbc, Inc. can grow by expanding its distribution network within China, targeting underserved regions and increasing its presence in existing markets. The Chinese pharmaceutical distribution market is estimated to be worth billions of dollars, offering significant potential for growth. Timeline: Ongoing.
- New Product Development: The company can invest in research and development to introduce new traditional Chinese medicines and biological pharmaceuticals, addressing unmet medical needs and expanding its product portfolio. The market for herbal medicines is growing, driven by increasing consumer awareness and acceptance. Timeline: Ongoing.
- Strategic Partnerships: Anbc, Inc. can form strategic partnerships with other pharmaceutical companies, research institutions, and distributors to leverage their expertise, resources, and market access. Partnerships can accelerate product development, expand market reach, and enhance competitiveness. Timeline: Ongoing.
- E-commerce and Online Sales: The company can establish an online presence and sell its products through e-commerce platforms, reaching a wider customer base and increasing sales. The online pharmaceutical market in China is growing rapidly, driven by increasing internet penetration and consumer adoption of online shopping. Timeline: Upcoming.
- International Expansion: Anbc, Inc. can explore opportunities to expand its operations and sell its products in international markets, particularly in regions with a significant Chinese diaspora and a growing interest in traditional Chinese medicine. The global market for herbal medicines is estimated to be worth billions of dollars. Timeline: Upcoming.
What Opportunities Does SYUP Have?
- Expanding distribution network within China.
- Developing new traditional Chinese medicines and biological pharmaceuticals.
- Forming strategic partnerships with other companies.
- Expanding into international markets.
What Threats Does SYUP Face?
- Competition from other pharmaceutical companies.
- Regulatory changes in the Chinese pharmaceutical market.
- Fluctuations in the Chinese economy.
- Potential for product liability claims.
What Are SYUP's Competitive Advantages?
- Proprietary formulations of traditional Chinese medicines.
- Established distribution network in China.
- Brand recognition in the Chinese market.
- Expertise in traditional Chinese medicine and biological pharmaceuticals.
What Does SYUP Do?
Shanghai Yutong Pharma, Inc., also known as Anbc, Inc. (SYUP), is a pharmaceutical company based in Shanghai, China, focused on the development, manufacturing, and commercialization of traditional Chinese herbal medicines and biological pharmaceuticals. The company's origins lie in addressing the healthcare needs within China by leveraging traditional medicine practices combined with modern pharmaceutical techniques. Its product portfolio includes a range of solutions targeting various health conditions. Key products include Qilisheng, designed to enhance the immune system; Qi-ju-di-huang, an oral solution aimed at protecting the kidney and liver; and Qing-re-jie-du, an oral solution to reduce fever and relieve heat. Additionally, they offer Sheng-mai-yin for energy enhancement, Xiao-qing-long for cough relief, Shen-bao syrup for treating impotence, Ban-xia syrup for cough, and Gan-mao-zhi-ke syrup for flu symptoms. The company also provides Ban-lan-gen and Gan-mao-qing-re for cold and flu symptoms, Huang-dan-yin-chen for jaundice treatment, and Liu-shen-qu for treating vomiting and dysentery. Shanghai Yutong Pharma distributes its products through wholesale channels to distributors across the People's Republic of China.
What Products and Services Does SYUP Offer?
- Develops traditional Chinese herbal medicines.
- Manufactures biological pharmaceuticals.
- Commercializes pharmaceutical products in China.
- Offers solutions for immune support.
- Provides medicines for kidney and liver protection.
- Creates solutions for cold and flu relief.
- Distributes products on a wholesale basis.
How Does SYUP Make Money?
- Develops and manufactures traditional Chinese medicines and biological pharmaceuticals.
- Sells products to distributors on a wholesale basis.
- Focuses on the Chinese market.
- Generates revenue through product sales.
What Industry Does SYUP Operate In?
Anbc, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, which is experiencing growth in China due to increasing healthcare expenditure and demand for traditional medicines. The market is competitive, with companies like BZAMF (Biozoom Inc.), CANQF (CannTrust Holdings Inc), COTQF (Cotinga Pharmaceuticals Inc), ETAOF (Ethaverse Inc), and FORU competing for market share. The Chinese pharmaceutical market is characterized by a mix of domestic and international players, with a growing emphasis on research and development of innovative therapies and traditional medicines. Regulatory changes and healthcare reforms are also shaping the industry landscape.
Who Are SYUP's Key Customers?
- Distributors of pharmaceutical products.
- Wholesale buyers of traditional Chinese medicines.
- Healthcare providers in China.
- Consumers seeking traditional Chinese medicine solutions.
ROE 86%Key Financial Metrics
Return on equity for Anbc, Inc. stands at 86.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 48.6%, showing how much profit it generates from its asset base. SYUP trades at a trailing price-to-earnings ratio of 0.01, below the Healthcare sector average of ~23x. A current ratio of 2.75 indicates the company holds enough short-term assets to cover its near-term obligations.
Anbc, Inc. (SYUP) Valuation Context
Valued at 16K, SYUP is classified as a micro-cap stock. Relative to its peer group, SYUP's quantitative score of 51/100 is below the peer average of 66/100.
Company Profile
Anbc, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Shanghai, CN. The company is led by CEO Wei Dong. SYUP has traded publicly since 2009.
SYUP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SYUP Latest News
No recent news available for SYUP.
SYUP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SYUP.
Price Targets
Wall Street price target analysis for SYUP.
SYUP MoonshotScore
What does this score mean?
The MoonshotScore rates SYUP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Wei Dong
CEO
Wei Dong is the Chief Executive Officer of Anbc, Inc. (Shanghai Yutong Pharma). Information regarding Mr. Dong's prior experience and educational background is not available. As CEO, he is responsible for overseeing the company's strategic direction, operations, and financial performance. His leadership is crucial in navigating the competitive pharmaceutical market in China and driving the company's growth initiatives.
Track Record: Information on Wei Dong's specific achievements and milestones as CEO of Anbc, Inc. is not available. His tenure and key strategic decisions are currently unknown. Further information is needed to assess his impact on the company's performance and growth.
SYUP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Anbc, Inc. (SYUP) may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it difficult for investors to assess their financial health and performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, potentially increasing investment risks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to OTC listing.
- Lack of transparency due to unknown disclosure status.
- Potential for fraud or manipulation in the OTC market.
- Limited regulatory oversight compared to major exchanges.
- Shell risk detected, indicating potential for reverse merger or other corporate restructuring.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags or warning signs, such as pending lawsuits or regulatory investigations.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Operations in the pharmaceutical sector, which requires regulatory approvals.
- Focus on traditional Chinese medicine, a recognized field.
- CEO leadership with Wei Dong.
- Physical headquarters in Shanghai, China.
Anbc, Inc. Healthcare Stock: Key Questions Answered
What does Anbc, Inc. do?
Anbc, Inc., operating as Shanghai Yutong Pharma, develops, manufactures, and commercializes traditional Chinese herbal medicines and biological pharmaceuticals. Its product portfolio includes solutions for immune support (Qilisheng), kidney and liver protection (Qi-ju-di-huang), and cold and flu relief (Gan-mao-zhi-ke). The company distributes its products on a wholesale basis within the People's Republic of China, focusing on traditional medicine practices combined with modern pharmaceutical techniques.
What are the main risks for SYUP?
The main risks for SYUP include limited liquidity due to its OTC listing, lack of transparency due to its unknown disclosure status, potential for fraud or manipulation in the OTC market, limited regulatory oversight compared to major exchanges, and shell risk. Additionally, the company faces competition from other pharmaceutical companies in China, regulatory changes in the Chinese pharmaceutical market, and fluctuations in the Chinese economy.
What are the key factors to evaluate for SYUP?
Anbc, Inc. (SYUP) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does SYUP data refresh on this page?
SYUP prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SYUP's recent stock price performance?
Anbc, Inc. (SYUP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the Chinese pharmaceutical market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SYUP overvalued or undervalued right now?
Valuing Anbc, Inc. (SYUP) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SYUP?
Before investing in Anbc, Inc. (SYUP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SYUP to a portfolio?
Key strength of Anbc, Inc. (SYUP): Established presence in the Chinese pharmaceutical market. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information on Wei Dong's background and track record is limited.
- Disclosure status on OTC markets is unknown, limiting financial transparency.
- AI analysis pending.